ALX Oncology Limited

ALX Oncology Limited

ALX Oncology was founded as a clinical-stage biotechnology company, advancing therapies that boost the immune system to treat cancer. The firm is publicly traded and headquartered in South San Francisco, California; its wealth origin is not applicable as it is not a family office. ALX Oncology's strategy centers on its lead therapeutic candidate, evorpacept, a high-affinity CD47-blocking fusion protein designed to enhance the immune system's attack on cancer cells while minimizing anemia common with earlier CD47-targeting agents. The company's portfolio includes evorpacept in combination with standard-of-care therapies for indications such as relapsed/refractory B-cell non-Hodgkin lymphoma, head and neck squamous cell carcinoma, and acute myeloid leukemia (per clinicaltrials.gov, 2025). The firm conducts development activities primarily in North America, with ongoing clinical trials at sites in the United States and internationally. The company is led by a team of experienced drug developers; specific executive names are not captured in available sources. As of 2025, ALX Oncology has not disclosed total employees or deployment capital. The firm has reported operational updates, including data readouts from Phase 1/2 trials, in the last 24 months. No adjacent vehicles such as a philanthropic foundation have been identified. A key structural differentiator is ALX Oncology's focus on evorpacept as a single lead asset, with a pipeline built entirely around its CD47-SIRPα mechanism. Unlike larger biopharmas, the firm operates as a clinical-stage entity with no approved products, relying on capital markets and partnerships to fund development. This narrow mandate reduces diversification but allows deep specialization in the immuno-oncology space.